{"transactions":[{"id":766063,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-22T21:37:58.000Z","date":"2026-05-21","kind":"other","planned":false,"acquired":false,"shares":23058,"price":4.47,"value":103069.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Issuer executed the sale to cover the tax liabilities arising from the vesting of an RSU award made on May 21, 2024."}],"balance_after":2337166,"source":{"system":"sec-edgar","filing":"0001079973-26-000725","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000107997326000725/ownership.xml","form_type":"4"}},{"id":822937,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-02T00:46:38.000Z","date":"2026-03-27","kind":"other","planned":false,"acquired":false,"shares":98534,"price":3.07,"value":302499.38,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The Issuer executed the sale to cover the tax liabilities arising from the vesting of an RSU award on March 31, 2026."}],"balance_after":2360224,"source":{"system":"sec-edgar","filing":"0001079973-26-000439","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000107997326000439/ownership.xml","form_type":"4"}},{"id":822936,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-02T00:46:38.000Z","date":"2026-03-27","kind":"grant","planned":false,"acquired":false,"shares":670608,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents RSU awards with 1/4 of the RSUs vesting on the first anniversary of the Vesting Commencement Date, with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates."}],"balance_after":2458758,"source":{"system":"sec-edgar","filing":"0001079973-26-000439","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000107997326000439/ownership.xml","form_type":"4"}},{"id":835082,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-18T21:21:35.000Z","date":"2026-03-17","kind":"other","planned":false,"acquired":false,"shares":11834,"price":3.59,"value":42484.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Issuer executed the sale to cover the tax liabilities arising from the vesting of an RSU award on March 17, 2026."}],"balance_after":1788150,"source":{"system":"sec-edgar","filing":"0001079973-26-000332","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000107997326000332/ownership.xml","form_type":"4"}},{"id":993907,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-11-19T23:03:11.000Z","date":"2025-11-17","kind":"grant","planned":false,"acquired":true,"shares":6464,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents RSU awards that were fully vested upon grant, net of withholding tax obligations."}],"balance_after":1799984,"source":{"system":"sec-edgar","filing":"0001079973-25-001809","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000107997325001809/ownership.xml","form_type":"4"}},{"id":998931,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-11-14T21:30:04.000Z","date":"2025-11-12","kind":"grant","planned":false,"acquired":true,"shares":6211,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents RSU awards that were fully vested upon grant, net of withholding tax obligations."}],"balance_after":1793520,"source":{"system":"sec-edgar","filing":"0001079973-25-001765","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000107997325001765/ownership.xml","form_type":"4"}},{"id":1137325,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2025-05-22T18:22:23.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20388,"price":2.675,"value":54537.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement."}],"balance_after":1787309,"source":{"system":"sec-edgar","filing":"0001628280-25-027210","document":"wk-form4_1747938137.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828025027210/wk-form4_1747938137.xml","form_type":"4"}},{"id":1183683,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2025-04-02T21:09:13.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":1083334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents RSU awards with 1/4th of the RSUs vesting on the first anniversary of the Vesting Commencement Date, with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates."}],"balance_after":1807697,"source":{"system":"sec-edgar","filing":"0001799191-25-000017","document":"wk-form4_1743628144.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919125000017/wk-form4_1743628144.xml","form_type":"4"}},{"id":1188880,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Warrant","published_at":"2025-03-28T21:50:27.000Z","date":"2025-03-26","kind":"purchase","planned":false,"acquired":true,"shares":11320,"price":0.125,"value":1415.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the \"Private Placement\"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock (\"Common Stock\") and a common warrant (\"Common Warrant\") to purchase one share of Common Stock (the \"Private Placement Unit\")."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the \"Private Placement\"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock (\"Common Stock\") and a common warrant (\"Common Warrant\") to purchase one share of Common Stock (the \"Private Placement Unit\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The reporting person may not exercise any portion of a Common Warrant to the extent that the reporting person would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately prior to or after giving effect to such exercise, as such percentage ownership is determined in accordance with Section 13(d) under the Exchange Act."}],"balance_after":11320,"derivative":{"exercise_price":1.198,"exercise_date":"2025-03-26","expiration_date":"2030-03-26","underlying":"Common Stock","underlying_shares":11320},"source":{"system":"sec-edgar","filing":"0001079973-25-000529","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000107997325000529/ownership.xml","form_type":"4"}},{"id":1188879,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-28T21:50:27.000Z","date":"2025-03-26","kind":"purchase","planned":false,"acquired":true,"shares":22640,"price":1.0417,"value":23584.088,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the \"Private Placement\"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock (\"Common Stock\") and a common warrant (\"Common Warrant\") to purchase one share of Common Stock (the \"Private Placement Unit\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250."}],"balance_after":724363,"source":{"system":"sec-edgar","filing":"0001079973-25-000529","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000107997325000529/ownership.xml","form_type":"4"}},{"id":1195771,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2025-03-20T22:01:37.000Z","date":"2025-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10261,"price":0.889,"value":9122.029,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement."}],"balance_after":701723,"source":{"system":"sec-edgar","filing":"0001799191-25-000008","document":"wk-form4_1742508091.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919125000008/wk-form4_1742508091.xml","form_type":"4"}},{"id":1355843,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2024-11-21T23:23:01.000Z","date":"2024-11-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4977,"price":0.136,"value":676.872,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price is the volume weighted average selling price of all sales by the Reporting Person on November 20, 2024 within a one-dollar range. Actual prices ranged from $0.136 to $0.168. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price."}],"balance_after":711984,"source":{"system":"sec-edgar","filing":"0001799191-24-000043","document":"wk-form4_1732231374.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919124000043/wk-form4_1732231374.xml","form_type":"4"}},{"id":1355842,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2024-11-21T23:23:01.000Z","date":"2024-11-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4750,"price":0.136,"value":646.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price is the volume weighted average selling price of all sales by the Reporting Person on November 20, 2024 within a one-dollar range. Actual prices ranged from $0.136 to $0.168. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price."}],"balance_after":716961,"source":{"system":"sec-edgar","filing":"0001799191-24-000043","document":"wk-form4_1732231374.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919124000043/wk-form4_1732231374.xml","form_type":"4"}},{"id":1361859,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2024-11-18T23:50:34.000Z","date":"2024-11-12","kind":"other","planned":false,"acquired":false,"shares":117142,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Reflects the forfeiture of restricted earn-out shares that were unvested due to failure to meet earnout targets of the Issuer's stock price of $15.00 per share for 20 days within any 30 consecutive trading days for the three-year period following November 12, 2021, the date of the closing of the Business Combination, subject to continued employment at such time."}],"balance_after":721711,"source":{"system":"sec-edgar","filing":"0001799191-24-000033","document":"wk-form4_1731973827.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919124000033/wk-form4_1731973827.xml","form_type":"4"}},{"id":1361858,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2024-11-18T23:50:34.000Z","date":"2024-11-12","kind":"other","planned":false,"acquired":false,"shares":78094,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Reflects the forfeiture of restricted earn-out shares that were unvested due to failure to meet earnout targets of the Issuer's stock price of $12.50 per share for 20 days within any 30 consecutive trading days for the three-year period following November 12, 2021, the date of the closing of the Business Combination, subject to continued employment at such time."}],"balance_after":838853,"source":{"system":"sec-edgar","filing":"0001799191-24-000033","document":"wk-form4_1731973827.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919124000033/wk-form4_1731973827.xml","form_type":"4"}},{"id":1503772,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-05-23T22:33:50.000Z","date":"2024-05-21","kind":"grant","planned":false,"acquired":true,"shares":496293,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options vest as to 1/4th of the options granted on the first anniversary of the Vesting Commencement Date, with the remaining options vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates."}],"balance_after":496293,"derivative":{"exercise_price":2,"expiration_date":"2034-05-21","underlying":"Common Stock","underlying_shares":496293},"source":{"system":"sec-edgar","filing":"0001799191-24-000011","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919124000011/edgardoc.xml","form_type":"4"}},{"id":1503771,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-05-23T22:33:50.000Z","date":"2024-05-21","kind":"grant","planned":false,"acquired":true,"shares":198517,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents RSUs with 1/4th of the RSUs vesting on the first anniversary of the Vesting Commencement Date, with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates."}],"balance_after":916947,"source":{"system":"sec-edgar","filing":"0001799191-24-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919124000011/edgardoc.xml","form_type":"4"}},{"id":1503770,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-05-23T22:33:50.000Z","date":"2024-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11173,"price":0.5972,"value":6672.5156,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement."}],"balance_after":718430,"source":{"system":"sec-edgar","filing":"0001799191-24-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919124000011/edgardoc.xml","form_type":"4"}},{"id":1731362,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2023-11-23T01:47:11.000Z","date":"2023-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4322,"price":2.193,"value":9478.146,"ownership":{"direct":true},"balance_after":729603,"source":{"system":"sec-edgar","filing":"0001628280-23-039911","document":"wk-form4_1700704014.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828023039911/wk-form4_1700704014.xml","form_type":"4"}},{"id":1739184,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2023-11-16T20:56:14.000Z","date":"2023-11-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4604,"price":2.385,"value":10980.54,"ownership":{"direct":true},"balance_after":733925,"source":{"system":"sec-edgar","filing":"0001628280-23-039300","document":"wk-form4_1700168164.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828023039300/wk-form4_1700168164.xml","form_type":"4"}},{"id":1943163,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-03-22T00:50:39.000Z","date":"2023-03-17","kind":"grant","planned":false,"acquired":true,"shares":287361,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest as to 1/4th of the options granted on the first anniversary of the Vesting Commencement Date, with the remaining options vesting in four equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates."}],"balance_after":287361,"derivative":{"exercise_price":0.481,"expiration_date":"2033-03-17","underlying":"Common stock","underlying_shares":287361},"source":{"system":"sec-edgar","filing":"0001628280-23-008830","document":"wf-form4_167944622505473.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828023008830/wf-form4_167944622505473.xml","form_type":"4"}},{"id":1943162,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common stock","published_at":"2023-03-22T00:50:39.000Z","date":"2023-03-17","kind":"grant","planned":false,"acquired":true,"shares":114944,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents RSUs with 1/4th of the RSUs vesting on the anniversary of March 17, 2023 (the Vesting Commencement Date), with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates."}],"balance_after":738529,"source":{"system":"sec-edgar","filing":"0001628280-23-008830","document":"wf-form4_167944622505473.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828023008830/wf-form4_167944622505473.xml","form_type":"4"}},{"id":2092310,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-12-09T00:02:26.000Z","date":"2022-12-07","kind":"exercise","acquired":false,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options vest as to 1/4th of the total number of shares subject to the option on the first anniversary of March 1, 2020 (the \"Original Grant Date\"), and as to 1/36th of the total number of shares monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Original Grant Date, subject to continued employment through the vest date."}],"balance_after":654609,"derivative":{"exercise_price":0.86,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001799191-22-000056","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919122000056/edgardoc.xml","form_type":"4"}},{"id":2092309,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-12-09T00:02:26.000Z","date":"2022-12-07","kind":"exercise","acquired":false,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest monthly for 36 months following November 12, 2021, the date of the closing of the Business Combination."}],"balance_after":829609,"derivative":{"exercise_price":0.86,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001799191-22-000056","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919122000056/edgardoc.xml","form_type":"4"}},{"id":2092308,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2022-12-09T00:02:26.000Z","date":"2022-12-07","kind":"exercise","acquired":true,"shares":175000,"price":0.86,"value":150500.0,"ownership":{"direct":true},"balance_after":623585,"source":{"system":"sec-edgar","filing":"0001799191-22-000056","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919122000056/edgardoc.xml","form_type":"4"}},{"id":2092307,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2022-12-09T00:02:26.000Z","date":"2022-12-07","kind":"exercise","acquired":true,"shares":175000,"price":0.86,"value":150500.0,"ownership":{"direct":true},"balance_after":448585,"source":{"system":"sec-edgar","filing":"0001799191-22-000056","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919122000056/edgardoc.xml","form_type":"4"}},{"id":2107029,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2022-11-23T01:08:53.000Z","date":"2022-11-15","kind":"sale","acquired":false,"shares":3767,"price":2.0278,"value":7638.7226,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4/A amends and restates the reporting persons Form 4 originally filed on November 17, 2022 in the entirety. This Form 4/A is being filed to correct the reporting persons original Form 4 from Code D to Code S. The sales reported in the Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price is the volume weighted average selling price of all sales by the Reporting Person on November 15, 2022 within a one-dollar range. Actual prices ranged from $2.025 to $2.028. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price."}],"balance_after":233484,"source":{"system":"sec-edgar","filing":"0001799191-22-000054","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919122000054/edgardoc.xml","form_type":"4/A","original_submission_date":"2022-11-17"}},{"id":2108739,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-11-21T22:36:28.000Z","date":"2022-11-17","kind":"grant","acquired":true,"shares":203543,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest as to 1/4th of the options granted on the first anniversary of the Vesting Commencement Date, with the remaining options vesting in four equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates."}],"balance_after":203543,"derivative":{"exercise_price":1.87,"expiration_date":"2032-11-17","underlying":"Common Stock","underlying_shares":203543},"source":{"system":"sec-edgar","filing":"0001799191-22-000044","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919122000044/edgardoc.xml","form_type":"4"}},{"id":2108738,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2022-11-21T22:36:28.000Z","date":"2022-11-17","kind":"grant","acquired":true,"shares":40101,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents RSUs with 1/4th of the RSUs vesting on the anniversary of November 17, 2022 (the Vesting Commencement Date), with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates."}],"balance_after":273585,"source":{"system":"sec-edgar","filing":"0001799191-22-000044","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919122000044/edgardoc.xml","form_type":"4"}},{"id":2112328,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2022-11-17T22:32:13.000Z","date":"2022-11-15","kind":"disposition_to_issuer","acquired":false,"shares":3767,"price":2.0278,"value":7638.7226,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price is the volume weighted average selling price of all sales by the Reporting Person on November 15, 2022 within a one-dollar range. Actual prices ranged from $2.025 to $2.028. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price."}],"balance_after":233484,"source":{"system":"sec-edgar","filing":"0001799191-22-000016","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919122000016/edgardoc.xml","form_type":"4"}},{"id":2315412,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-30T00:11:00.000Z","date":"2022-03-21","kind":"grant","acquired":true,"shares":213259,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest in four equal annual installments on each of the first four anniversaries of November 12, 2021 (the \"Vesting Commencement Date\"), with all options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates."}],"balance_after":213259,"derivative":{"exercise_price":7.09,"expiration_date":"2032-03-21","underlying":"Common stock","underlying_shares":213259},"source":{"system":"sec-edgar","filing":"0001628280-22-007761","document":"wf-form4a_164859904637538.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828022007761/wf-form4a_164859904637538.xml","form_type":"4/A","original_submission_date":"2022-03-23"}},{"id":2320132,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-23T23:36:06.000Z","date":"2022-03-21","kind":"grant","acquired":true,"shares":34121,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest in four equal annual installments on each of the first four anniversaries of the Vesting Commencement Date, with all options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates."}],"balance_after":34121,"derivative":{"exercise_price":7.09,"expiration_date":"2032-03-21","underlying":"Common stock","underlying_shares":34121},"source":{"system":"sec-edgar","filing":"0001628280-22-007098","document":"wf-form4_164807854570402.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828022007098/wf-form4_164807854570402.xml","form_type":"4"}},{"id":2320131,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common stock","published_at":"2022-03-23T23:36:06.000Z","date":"2022-03-21","kind":"grant","acquired":true,"shares":42015,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") that vest in four equal annual installments on each of the first four anniversaries of November 12, 2021 (the \"Vesting Commencement Date\"), with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\") that vest in four equal annual installments on each of the first four anniversaries of November 12, 2021 (the \"Vesting Commencement Date\"), with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates."}],"balance_after":237251,"source":{"system":"sec-edgar","filing":"0001628280-22-007098","document":"wf-form4_164807854570402.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000162828022007098/wf-form4_164807854570402.xml","form_type":"4"}},{"id":2510846,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options (right to buy)","published_at":"2021-11-17T02:54:24.000Z","date":"2021-11-12","kind":"grant","acquired":true,"shares":578006,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"These stock options were received in connection with the Business Combination in exchange for performance based stock options to acquire shares of Old TOI, and reflect holder's allocated share of the stock consideration pursuant to the Merger Agreement.These options vest monthly for 36 months following November 12, 2021, the date of the closing of the Business Combination, subject to continued employment through the vest date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These stock options were received in connection with the Business Combination in exchange for performance based stock options to acquire shares of Old TOI, and reflect holder's allocated share of the stock consideration pursuant to the Merger Agreement.These options vest monthly for 36 months following November 12, 2021, the date of the closing of the Business Combination, subject to continued employment through the vest date."}],"balance_after":68208,"derivative":{"exercise_price":0.86,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":578006},"source":{"system":"sec-edgar","filing":"0001104659-21-140221","document":"tm2132979-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000110465921140221/tm2132979-11_4seq1.xml","form_type":"4"}},{"id":2510845,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options (right to buy)","published_at":"2021-11-17T02:54:24.000Z","date":"2021-11-12","kind":"grant","acquired":true,"shares":426603,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"These stock options were received in connection with the Business Combination in exchange for time-vested stock options to acquire shares of Old TOI, and reflect holder's allocated share of the stock consideration pursuant to the Merger Agreement. These options vest as to 1/4th of the total number of shares subject to the option on the first anniversary of November 16, 2020 (the \"Original Grant Date\"), and as 1/36th of the total number of shares monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Original Grant Date, subject to continued employment through the vest date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These stock options were received in connection with the Business Combination in exchange for time-vested stock options to acquire shares of Old TOI, and reflect holder's allocated share of the stock consideration pursuant to the Merger Agreement. These options vest as to 1/4th of the total number of shares subject to the option on the first anniversary of November 16, 2020 (the \"Original Grant Date\"), and as 1/36th of the total number of shares monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Original Grant Date, subject to continued employment through the vest date."}],"balance_after":426603,"derivative":{"exercise_price":0.86,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":426603},"source":{"system":"sec-edgar","filing":"0001104659-21-140221","document":"tm2132979-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000110465921140221/tm2132979-11_4seq1.xml","form_type":"4"}},{"id":2510844,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-11-17T02:54:24.000Z","date":"2021-11-12","kind":"grant","acquired":true,"shares":117142,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $12.50 per share for 20 days within any 30 consecutive trading days for the two-year period following the closing of the Business Combination, subject to continued employment at such time."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"On November 12, 2021, pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as June 28, 2021, by and among DFP Healthcare Acqusitions Corp. (\"DFP\"), Orion Merger Sub I, Inc. (\"First Merger Sub\"), Orion Merger Sub II, LLC (\"Second Merger Sub\"), and TOI Parent, Inc. (\"Old TOI\"), First Merger Sub merged into Old TOI, with Old TOI being the surivivng corporation then Old TOI merged into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly owned subsidiary of DFP, which then changed its name to The Oncology Institute, Inc. (such transactions, collectively, the \"Business Combination\"). Upon consummation of the Business Combination, each issued and outstanding share of common stock of Old TOI was automatically cancelled and the holder thereof was entitled to receive its allocable share of cash and stock consideration pursuant to the Merger Agreement converted into shares of Common Stock of the Issuer."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F3","text":"The shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $15.00 per share for 20 days within any 30 consecutive trading days for the three-year period following the closing of the Business Combination, subject to continued employment at such time."}],"balance_after":195236,"source":{"system":"sec-edgar","filing":"0001104659-21-140221","document":"tm2132979-11_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000110465921140221/tm2132979-11_4seq1.xml","form_type":"4"}},{"id":2510843,"issuer":{"id":5327,"kind":"organization","name":"Starling Oncology, Inc."},"owners":[{"id":44753,"kind":"person","name":"Virnich Daniel","position":1,"cik":"0001891107","reported_name":"Virnich Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-11-17T02:54:24.000Z","date":"2021-11-12","kind":"grant","acquired":true,"shares":78094,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $12.50 per share for 20 days within any 30 consecutive trading days for the two-year period following the closing of the Business Combination, subject to continued employment at such time."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"On November 12, 2021, pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as June 28, 2021, by and among DFP Healthcare Acqusitions Corp. (\"DFP\"), Orion Merger Sub I, Inc. (\"First Merger Sub\"), Orion Merger Sub II, LLC (\"Second Merger Sub\"), and TOI Parent, Inc. (\"Old TOI\"), First Merger Sub merged into Old TOI, with Old TOI being the surivivng corporation then Old TOI merged into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly owned subsidiary of DFP, which then changed its name to The Oncology Institute, Inc. (such transactions, collectively, the \"Business Combination\"). Upon consummation of the Business Combination, each issued and outstanding share of common stock of Old TOI was automatically cancelled and the holder thereof was entitled to receive its allocable share of cash and stock consideration pursuant to the Merger Agreement converted into shares of Common Stock of the Issuer."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"These shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $12.50 per share for 20 days within any 30 consecutive trading days for the two-year period following the closing of the Business Combination, subject to continued employment at such time."}],"balance_after":78094,"source":{"system":"sec-edgar","filing":"0001104659-21-140221","document":"tm2132979-11_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799191/000110465921140221/tm2132979-11_4seq1.xml","form_type":"4"}}]}